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Over the last decade the amino acid beta-N-methylamino-L-alanine (BMAA) has come under intense scrutiny.
International laboratory and epidemiological research continues to support the hypothesis that environmental
exposure to BMAA (e.g., through dietary practices, water supply) can promote the risk of various neurodegenerative
diseases. A wide variety of cyanobacteria spp. have previously been reported to produce BMAA, with production levels
dependent upon species, strain and environmental conditions. Since spirulina (Arthrospira spp.) is a member of the
cyanobacteria phylum frequently consumed via dietary supplements, the presence of BMAA in such products may have
public health implications. In the current work, we have analyzed ten spirulina-containing samples for the presence
of BMAA; six pure spirulina samples from two separate raw materials suppliers, and four commercially-available
multi-ingredient products containing 1.45 g of spirulina per 8.5 g serving. Because of controversy surrounding the
measurement of BMAA, we have used two complementary liquid chromatography-tandem mass spectrometry
(LC-MS/MS) methods: one based on reversed phase LC (RPLC) with derivatization and the other based on hydrophilic
interaction LC (HILIC). Potential matrix effects were corrected for by internal standardization using a stable isotope
labeled BMAA standard. BMAA was not detected at low limits of detection (80 ng/g dry weight) in any of these
product samples. Although these results are reassuring, BMAA analyses should be conducted on a wider sample
selection and, perhaps, as part of ongoing spirulina production quality control testing and specifications.
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Over the last decade, an increasingly robust body of
bench and epidemiological research has suggested that
β-N-methylamino-L-alanine (BMAA) may play a role in
various neurodegenerative diseases [1,2]. BMAA is a
non-proteinogenic amino acid first identified in the
seeds of Cycas micronesia in 1967 [3]. It was noted in
the 1980s [4] and revisited again in 2002 [5], that cycad
pulp and seed flour (as well as animals that fed upon
cycad seeds) have been a significant part of the traditional
dietary and medicinal agents among specific Western
Pacific-dwelling communities (e.g. Guam). Based on
experimental evidence of BMAA-induced neurotoxicity,
these research groups theorized that a high incidence of* Correspondence: michael.quilliam@nrc-cnrc.gc.ca
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unless otherwise stated.neurodegenerative diseases in these regions may be
associated with dietary intake of BMAA [4,5]. Investiga-
tions would confirm that BMAA is found in various
dietary items along the regional food chain within these
communities and that BMAA can accumulate in animal
tissue over time [6].
Initially thought to be a relatively isolated concern trace-
able to the Cycas, and its seeds in particular, BMAA was
reported in the brain tissue of a small sample of Canadian
adults who had died in association with Alzheimer’s dis-
ease [7]. BMAA was not found in controls that had died
from causes other than neurodegenerative. This suggested
that BMAA may not merely be a local concern for those
in Micronesia. A 2003 report indicated that BMAA was
being produced by cyanobacteria that live in symbiotic
fashion with the Cycas roots [8]. Subsequently, a study of
29 specific strains of free-living cyanobacteria (derived
from marine, freshwater and brackish sources) showedral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cyanobacteria used in the study were drawn from diverse
taxa, and given the ubiquity of the phylum cyanobacteria
itself, the implications to public health could be significant.
Uncovering potential mechanisms of BMAA neurotox-
icity is an area of intense research. Recent experimental
studies indicate that BMAA induces oxidative stress and
excitotoxicity, and the agent may be misincorporated into
nerve cell proteins, causing neuronal damage [10,11].
These studies are matched by emerging epidemiological
work suggesting that residential proximity to cyanobaterial-
contaminated lakes is associated with increased risk of
amyotrophic lateral sclerosis (ALS) [12,13]. Given the pro-
gress in this area, it is surprising that a significant source of
direct cyanobacterial intake - spirulina-containing dietary
supplements - have not been investigated for the presence
or absence of BMAA.
Within the Arthrospira genus of cyanobacteria, Arthros-
pira platensis is a dietary supplement commonly referred
to as ‘spirulina’. Although spirulina is sold as a stand-alone
supplement, it is frequently incorporated into so-called
‘green drink’ supplements, those inclusive of a variety of
fruit, vegetable, herbal and aquatically-derived extracts in
powdered form. The dose of spirulina within these supple-
ments is usually significant, typically ranging between 1–2
grams per serving. Given that such supplements are mar-
keted for continuous use, the presence of BMAA would be
cause for legitimate concern. Although commonly referred
to as a “blue-green algae”, and remarkably still remains
technically classified as a botanical under the existing rules
of the International Code of Nomenclature of Prokaryotes,
spirulina actually belongs to the phylum Cyanobacteria and
lack the nuclei of algae [14].
We could find only a single published study, one con-
ducted by Health Canada’s Bureau of Chemical Safety [15],
which examined 11 “blue-green algae” containing food sup-
plements for BMAA content. Using a liquid chromato-
graphic method, the investigators found no BMAA to a
detection limit of 200 ng/g. The researchers were able to
recover up to 89% of BMAA when they intentionally spiked
the supplements with BMAA, lending credibility to their
findings. However, despite making note of the connection
between BMAA and cyanobacterium spp. as a background
to their investigation, within the methods section the group
used only the broad term of “blue-green algae food sup-
plements” and they did not specify species or provide a
detailed description of the algae within the 11 products in
question. It is unclear if the researchers were intending to
examine spirulina, underscoring the need for proper no-
menclature. Therefore, the presence/absence of BMAA in
products specifically listing spirulina (or Arthrospira spp.)
as an ingredient remains an open question.
Furthermore, advanced analytical techniques have since
allowed for improved detection of BMAA [16-20], includingmethodology that allows for the consideration of reactivity
between BMAA and metal ions [21]. Advanced techniques
indicate that the broad assumption that all (or 90% plus)
members of the cyanobacterial taxa are BMAA producers
may be incorrect [22]. Indeed, the most extensive review
of the topic to date [23] has suggested that many of the
assumptions related to the presence of BMAA in aquatic
biosystems are based on a background of inadequate
analytical methods and false positives. This same review
highlights that liquid chromatography-mass spectrometry
(LC-MS/MS) is currently regarded as the most suitable
method to confirm the presence of BMAA and measure
its concentration in samples. Still, to the best of our know-
ledge, researchers have not specifically looked for BMAA
in edible spirulina samples. Given the international popu-
larity of spirulina as a dietary supplement [24,25], particu-
larly in the context of “green drinks”, we have determined
the BMAA content of ten spirulina samples using two LC-
MS/MS methods. Our samples were comprised of six raw
material samples of pure spirulina (derived from two sep-
arate suppliers) and four commercially available Canadian
spirulina-containing dietary supplements.Methods
Reagents
BMAA (β-N-methylamino-L-alanine hydrochloride, B107,
10 mg) was obtained from Tocris Bioscience (distributor:
R&D systems, Minneapolis, MN), AEG (N-(2-aminoethyl)-
glycine) was from TCI America chemicals (Portland, OR),
and DAB (DL-2,4-diaminobutyric acid dihydrochloride,
B3758, 1 g) was from Sigma Aldrich (Oakville, ON Canada).
Ammonium formate (99%), sodium hydroxide, d3-
methylamine hydrochloride, 2-acetamidoacrylic acid, and
hydrochloric acid were purchased from Sigma Aldrich
(Oakville, ON, Canada). Distilled-in-glass ethanol and
methanol and HPLC grade acetonitrile were obtained from
Caledon (Georgetown, ON, Canada) or BDH Inc. (Toronto,
ON, Canada). Formic acid (>98% ACS grade) was obtained
from EMD (Gibbstown, NJ, USA). The internal standard,
d3-BMAA, was synthesized in-house following previously
outlined procedures with some modifications [17,26,27]. In
a round bottom flask a solution of d3-methyl amine hydro-
chloric acid (1 g in 4 mL of water) was cooled to 4°C.
Sodium hydroxide (0.88 g) was added while stirring and the
reaction was allowed to warm to room temperature. Then
2-acetamidoacrylic acid (0.37 g) was added and stirred
without heat for 10 min. On a heating mantle the reaction
temperature was brought to 35°C for 22 hr. After cooling
to room temperature the mixture was dried using a rotary
evaporator and the crude product was dissolved in a mini-
mum volume of 3 M HCl and refluxed for 2 hr. The HCl
was removed and the residue recrystallized from ethanol
and water at 4°C. The resulting crystals were collected by
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ture of the product d3-BMAA was verified by NMR.
Samples and preparation
Spirulina samples, ten in total, included six samples of raw
spirulina furnished from two separate spirulina manufac-
turers, and four samples of multi-ingredient “green drink”
products that were inclusive of 1.45 g of spirulina per serv-
ing. All samples were forwarded with commercial labels
removed and coded as #1-10, i.e., all samples arrived to
the NRC office as blind samples. The samples were stored
at room temperature until analysis by LC-MS/MS. A posi-
tive control Cycad plant (Cycas debaoensis) was obtained
from Jurassic Plants Nursery (Halfmoon Bay, BC). Leaves
of the cycad plant were chopped into fine pieces using a
scalpel and then freeze-dried in preparation for extraction
and analysis.
Bulk samples were thoroughly mixed and 10 mg ali-
quots were transferred to glass extraction tubes. A 20 μL
aliquot of d3-BMAA internal standard was added to each
sample and then 1 mL of 6 mM HCl was added and vor-
tex mixed. The tubes were purged with nitrogen, covered
with Teflon tape, capped and maintained at 110°C for
18 hr in order to determine “total BMAA”. When cool,
the hydrolyzed sample extracts were filtered (0.22 μm
Ultrafree-MC) and then dried under nitrogen at 55°C and
reconstituted in 1.0 mL of 2 mM HCl. For RPLC the
extracts were derivatized as described below. For HILIC a
100 μL aliquot of each filtered sample was dried under
nitrogen and reconstituted in 100 μL of acetonitrile/water
(65:35).
AQC derivatization
AccQ-Tag kit reagent (Waters, Milford, MA, USA) was
prepared according to the manufacturer’s instructions. For
AQC derivatization, 40 μL of sample extract (dissolved in
2 mM HCl) was placed in a clean LC vial and dried thor-
oughly under a nitrogen stream at 55°C. The residue was
reconstituted in 120 μL of AccQfluor borate buffer solu-
tion and vortex mixed. A 40 μL aliquot of AQC reagent
solution was added and vortex mixed. The solution was
allowed to sit at room temperature for 1 min and then
heated at 55°C for 10 min before transfer to an LC insert
vial for LC-MS/MS.
LC-MS/MS
Quantitative measurement of BMAA, DAB and AEG as
AQC derivatives was performed using RPLC-MS/MS on
an Agilent 1200 LC system (Agilent Inc., Palo Alta, CA)
connected to an API4000 QTRAP mass spectrometer
(AB Sciex, Concord, ON, Canada) using electrospray
ionization and selected reaction monitoring. Direct
quantitation of BMAA, DAB and AEG by HILIC-MS/
MS on an Agilent 1100 LC system connected to an API4000 mass spectrometer. Table 1 provides the experi-
mental details for the two methods.
Results and discussion
Two complementary LC-MS/MS methods were used in
the present study for the analysis of BMAA in hydro-
lysed spirulina-containing ‘green drink’ supplements
with an extraction procedure aimed at providing “total
BMAA” concentration, i.e., free plus protein-bound.
One method was based on reversed phase LC (RPLC)
with derivatization using 6-aminoquinolyl-N-hydroxy-
succinimidylcarbamate (AQC) [16-19] and the other
used hydrophilic interaction LC (HILIC) without deriv-
atization [18]. Two other compounds, 2,4-diaminobu-
tyric acid (DAB) and N-(2-aminoethyl)-glycine (AEG),
were also monitored since they are isomeric with BMAA
and have been reported in cyanobacterial samples [19,20].
A stable-isotope labeled internal standard, d3-BMAA, was
used as internal standard in both methods to correct for
extraction recovery and matrix effects, the latter being
commonly observed in electrospray LC-MS/MS. Although
better detection limits could have been achieved with solid
phase extraction [18], such cleanup of samples was not
used in this study because of concerns expressed in the
literature [21] that BMAA might be lost during such
procedures.
Significant attention was paid to ensuring good separ-
ation of BMAA from isomeric compounds. There are
many possible isomers of BMAA but the primary ones of
concern are AEG and DAB. Good separations of BMAA
from AEG and DAB were achieved in both RPLC and
HILIC methods. Retention times for BMAA, AEG and
DAB were 6.62, 6.31 and 7.17 min for RPLC (see Figure 1)
and 18.46, 20.59 and 19.60 min for HILIC (data not
shown), respectively. Target analytes were all baseline
resolved as shown in Figure 1. The d3-BMAA internal
standard eluted slightly earlier by 0.02 min than the un-
labeled BMAA in RPLC and slightly later by 0.06 min in
HILIC, but it was deemed that the peaks were sufficiently
co-eluting in both methods as required for correction of
matrix effects.
The selected reaction monitoring (SRM) transitions
used for detecting BMAA and its isomers compounds
are detailed in the Methods section (Table 1). A total of
6 transitions were used for detecting BMAA, AEG and
DAB, three of which were common to all compounds
and three of which were selective to each compound
(see Figure 1). Unfortunately, the compound specific
signals were much weaker and are therefore only useful
for higher levels. The ratios of the transition intensities
as well as the retention times relative to d3-BMAA were
used as criteria for identification of the compounds. Ex-
cellent linearity of response was observed for the two
methods (R2 > 0.99).
Table 1 Experimental conditions for LC-MS/MS analyses
Method 1: AQC-RPLC-MS/MS Method 2: HILIC-MS/MS
Derivatization AQC none
Chromatography RPLC HILIC
Stationary phase Thermo Hypersil Gold C18 TosohBioscience TSK-gel Amide-80
Column length × I.D. (mm) 50 × 2 250 × 2
Column packing size (μm) 1.9 5.0
Column temp (°C) 20 40
Mobile phase A Water with 20 mM NH4COOH (pH 5 adjusted) Water with 50 mM HCOOH
Mobile phase B Methanol Acetonitrile: Water (95:5) with 50 mM HCOOH
Flow rate (mL/min) 0.40 0.20
Injection volume (uL) 6.0 5.0
Elution conditions 10-40% B in 6 min, to 85% B at 6.1 min, hold at 85% B
until 8.5 min.
90 to 60% B in 15 min, hold to 20 min, decrease to 55% B
at 21 min, hold to 30 min.
MS Ionization Positive electrospray (Turbospray®) Positive electrospray (Turbospray®)
MS source temp (°C) 450 450
MS ionization voltage (V) 5500 5500





SRM transitions for: Precursor m/z Product m/z CE (V) BMAA DAB AEG Precursor m/z Product m/z CE (V) BMAA DAB AEG
1 BMAA, DAB, AEG 459.2 171.1 35 1.00 1.00 1.00 119.1 102.1 15 1.00 0.40 1.00
2 BMAA, DAB, AEG 459.2 119.1 30 0.28 0.07 0.28 119.1 101.1 20 0.55 1.00 0.65
3 BMAA, DAB, AEG 459.2 289.1 20 0.39 0.13 0.27 - - - - - -
4 BMAA specific 459.2 258.1 30 0.04 na na 119.1 88.1 20 0.29 na na
5 DAB specific 459.2 188.1 35 na 0.02 na 119.1 74.1 25 na 0.11 na
6 AEG specific 459.2 214.1 35 na na 0.02 - - - - - -
7 d3-BMAA 462.2 292.1 20 1.0 na na 122.1 105.1 15 1.00 na na
8 d3-BMAA 462.2 122.1 30 0.7 na na 122.1 88.1 20 0.24 na na
8 mono-AQC BMAA 230.1 171.1 30 na na na na na na na na na
9 di-AQC lysine 487.2 171.1 25 na na na na na na na na na
10 mono-AQC lysine 317.1 171.1 30 na na na na na na na na na
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calibration standards and were defined as the level at
which there was a signal to noise ratio of 3. The LODs
for the AQC-RPLC-MS/MS method were 80, 36 and
211 ng/g (dry weight) for BMAA, AEG and DAB, re-
spectively. The corresponding LODs for HILIC-MS/MS
were 93, 44 and 205 ng/g (dry weight). The absence of a
signal for BMAA along with the presence of a signal for
the d3-BMAA spike can be considered very good proof
of absence (above the LOD) of BMAA in samples.
The suitability of the two methods, from sample
extraction through to analysis, was tested with a positive
control: an extract of leaves from a Cycad plant (Cycas
debaoensis) (data not shown), which, as previously dis-
cussed, is known to support cyanobacterium spp. that
produce BMAA. BMAA was detected and confirmed to
be present at ~220 μg/g (dry weight).Table 2 summarizes the results for the various samples
analyzed. BMAA was not detected in any of the samples
by either LC-MS/MS method. DAB and AEG were
detected and confirmed in all samples at levels between
190 and 2600 ng/g (dry weight). Figure 2 shows a typical
data set from the RPLC-MS/MS analysis of sample #7.
No BMAA signal could be detected but signals for AEG,
DAB and d3-BMAA were clearly observed at their cor-
rect retention times, which were very reproducible with
less than 1% variation between samples. Measuring re-
tention times relative to that of d3-BMAA allowed ex-
cellent matching (see Table 2). A number of peaks of
unknown identity were observed at various retention
times different than the target analytes, but are often
only observed in one or two transition channels. This in-
dicates the importance of using at least two, preferably
three, SRM transitions for confirmation of compound
Figure 1 Chromatograms from AQC-RPLC-MS/MS analysis
of standards.
Figure 2 Chromatograms from AQC-RPLC-MS/MS analysis of
sample 7 spiked with 1 μg/g d3-BMAA.
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close to AQC-derivatized AEG with a signal in the m/z
459 > 289 channel was observed at a low level (marked
with an asterisk in Figure 2). We observed that this peak
shifted its position relative to other peaks, sometimes
approaching that of BMAA, when a new mobile phase
batch with a slightly different pH was used. Analysis of the
samples by the HILIC-MS/MS method were somewhat
complicated by the effect of matrix on retention times,Table 2 Relative retention times (RRTs) and
concentrations (ng/g) measured for AEG, BMAA and DAB
in samples and in Cycad control material as analyzed by
the RPLC-MS/MS method
RRTs* Concentrations (ng/g)**
Sample # AEG BMAA DAB AEG BMAA DAB
GH-1 nd nd 1.08 nd nd 1226
GH-2 0.96 nd 1.09 290 nd 2493
GH-3 0.96 nd 1.09 191 nd 1773
GH-4 0.96 nd 1.09 569 nd 2569
GH-5 0.96 nd 1.09 1348 nd 874
GH-6 0.96 nd 1.09 1240 nd 1599
GH-7 0.96 nd 1.09 1136 nd 963
GH-8 0.96 nd 1.09 486 nd 490
GH-9 0.96 nd 1.09 290 nd 1270
GH-10 0.96 nd 1.09 500 nd 696
Cycad (NRC) 0.96 1.003 1.08 375 208,089 631
*relative to d3-BMAA (RT = 6.60 min).
**internal standard quantitation was used for BMAA, while external calibration.
nd = not detected (LOD = 80 ng/g for BMAA).
Retention times are expressed relative to a d3-BMAA internal standard that
was spiked into the individual samples.which shifted to earlier positions in the presence of matrix.
Spikes of samples with BMAA confirmed, however, that
d3-BMAA and BMAA still essentially co-eluted and the
absence of a BMAA signal in samples could still be de-
termined. This problem can be overcome with an SPE
cleanup of the sample [18] and this will be used in future
studies.
Recorded use of spirulina for medicinal and dietary use
dates back to the 16th Century [14]. It has enjoyed a good
degree of safety and a low risk of toxicity within the
in vitro and in vivo models (although as mentioned, these
have not addressed BMAA) [28]. Amidst concerns related
to cyanobacteria spp. and neurodegenerative diseases, it is
worth pointing out that spirulina has been the subject of a
number of studies related to the brain and nervous sys-
tem, with outcomes demonstrating benefit even in models
of developmental origins of health and disease [29-33].
For example, oral spirulina administration has been shown
to protect against experimentally-induced neural tube
defects [34] and spirulina-enhanced diets afford neuropro-
tection in experimental models of Parkinson’s disease [35].
The anti-inflammatory and antioxidant properties of the
agent in the context of neuroprotection have been well
described [36].
In 2011, the Dietary Supplements Information Expert
Committee of the United States Pharmacopeial Convention
(USP) reviewed human and experimental studies, as well
as regulatory and pharmacopeial sources before assigning
Spirulina maxima and Spirulina platensis a Class A safety
rating. Thus, these primary forms of spirulina, those most
commonly found in supplements, became part of the
National Formulary of the USP, a compendia recognized by
the United States Food, Drug, and Cosmetic Act. However,
the Expert Committee of the USP did acknowledge that
the unknowns related to spirulina and BMAA were a valid
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quality controls [14]. We agree. Indeed, although BMAA
was not detected in any of the raw materials and finished
product samples tested here, researchers have reported
that BMAA production in various Cyanobacteria spp. is
dependent upon nutrient availability and other environ-
mental conditions [37]. Therefore, in an effort to ensure
consumer safety and following the precautionary principle
regarding the emerging BMAA research, routine testing
using techniques such as those outlined in the current
study should be given wider consideration by spirulina
harvesters as part of standard quality controls.Conclusions
Previous research using older methodology has suggested
that species from a wide variety of cyanobacteria phyla are
capable of producing the neurotoxin BMAA. International
studies indicate that BMAA may accumulate in tissue over
time, suggesting that the regular consumption of dietary
products containing BMAA is of concern to public health.
Spirulina is a cyanobacterium widely consumed as a diet-
ary supplement. Moreover, spirulina has emerged as an
attractive and nutritious component of animal feed [38];
therefore the opportunity for biomagnification of BMAA
into the food supply, should it be present in spirulina, is
strong. Although spirulina has been found to have neuro-
protective properties in various models, it had not, to the
best of our knowledge, been subjected to research for
BMAA determination – perhaps due to the positive find-
ings on its neurological benefits.
Here, we have evaluated commercially available ‘green
drink’ dietary supplements containing significant amounts
of spirulina. Using two advanced LC-MS/MS techniques,
we were unable to detect BMAA to a level of 80 ng/g in
any of the product samples. Although reassuring, the
small sample of pure spirulina and spirulina-containing re-
tail products can only be considered as a preliminary step
toward larger investigations and evaluation of quality con-
trol in spirulina production. In the often conflicting
research surrounding the presence of BMAA in aquatic
biosystems and products derived from fresh and marine
waters, the use of LC-MS/MS is emerging as a gold stand-
ard with which to expand upon these discussions. The
next steps should focus on inter-laboratory comparison
studies and the production of certified reference materials
for quality control of analyses.
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